Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325876 | 1.00 | HRH3 (0.50) | HRH3EPHX2GFERALDH1A1MAPT | |
| SCHEMBL3329336 | 0.90 | EPHX2 (0.43) | HRH3EPHX2GFERALDH1A1MAPT | |
| SCHEMBL3329332 | 0.90 | EPHX2 (0.43) | HRH3EPHX2GFERALDH1A1MAPT | |
| SCHEMBL3326514 | 0.87 | HRH3 (0.54) | HRH3GFERALDH1A1L3MBTL1MLNR | |
| SCHEMBL3327503 | 0.87 | HRH3 (0.54) | HRH3GFERALDH1A1L3MBTL1MLNR | |
| SCHEMBL3326510 | 0.87 | HRH3 (0.54) | HRH3GFERALDH1A1L3MBTL1MLNR | |
| SCHEMBL3327437 | 0.83 | ALDH1A1 (0.46) | HRH3EPHX2ALDH1A1MAPTKDM4E | |
| SCHEMBL3327432 | 0.83 | ALDH1A1 (0.46) | HRH3EPHX2ALDH1A1MAPTKDM4E | |
| SCHEMBL3327453 | 0.80 | L3MBTL1 (0.43) | HRH3EPHX2GFERALDH1A1L3MBTL1 | |
| SCHEMBL3330093 | 0.80 | DRD2 (0.48) | MAPTL3MBTL1MLNRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | HRH3 1/4885EPHX2 3709/4885GFER 3334/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | HRH3 1/4885EPHX2 3709/4885GFER 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.